AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01298661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Six-minute Step Test
Description: The patients underwent a test where they need to step up and down a 20cm test during six minutes.
Study NCT01462396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD34+ cells selected with the Miltenyi Clinimacs machine
Description: Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
Study NCT02147288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renasys*GO Negative Pressure Wound Therapy System
Description: Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
Study NCT04201613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic exoskeleton
Description: The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
Study NCT04201613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive standard care with no additional therapy.
Study NCT04600583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)
Description: All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
Study NCT03589027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel two rod sub-dermal implant
Description: Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
Study NCT03589027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Oral ripilvirine 25mg once daily
Study NCT02159664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: didgeridoo practice
Description: instrument lessons, 1X/w and daily practice, 20 min /d
Study NCT02822469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Treatment
Description: Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes.
Study NCT02822469 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
Study NCT01794052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence based, DSS enabled, health care delivery model
Description: The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm
Study NCT01440738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health workshops
Description: health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
Study NCT01050985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus and capecitabine
Description: temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
Study NCT00696137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Fentanyl
Description: buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
Study NCT03589027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir+Ritonavir
Description: Oral DRV/r 600/100mg twice daily
Study NCT03848741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB+VitD
Description: Participants will be given HMB+VitD capsules to consume for 12-weeks
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone cream applied daily for two weeks
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nesiritide
Description: Administered IV once during the study
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Administered IV once during the study
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leuprolide
Description: Administered twice during the study by injection
Study NCT03981627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADO09 formulation
Description: Subcutaneous injection of ADO09 formulation
Study NCT03981627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid®
Description: Subcutaneous injection of insulin aspart
Study NCT02990676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training
Description: Computerised cognitive training regime
Study NCT04371601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir capsules
Study NCT04371601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules
Study NCT04371601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormones
Description: a moderate amount of hormone
Study NCT04371601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormones
Description: a moderate amount of hormone
Study NCT04371601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen therapy
Description: oxygen therapy,mechanical ventilation and other supportive therapies
Study NCT04371601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: oxygen therapy,mechanical ventilation and other supportive therapies
Study NCT04371601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells
Study NCT00863291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine
Description: buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
Study NCT00863291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo in a manner similar to the active comparator
Study NCT02922426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Daily dosing for 21 consecutive days
Study NCT02922426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily dosing for 21 consecutive days
Study NCT02922426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing for 21 consecutive days
Study NCT00869518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifabutin plus trimethoprim sulfamethoxazole
Description: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
Study NCT00869518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus trimethoprim-sulfamethoxazole
Description: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
Study NCT01281033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Thrombectomy
Description: In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
Study NCT01281033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AngioJet Rheolytic Thrombectomy (RT) System
Description: The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
Study NCT04382742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Resistance Exercises
Description: Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
Study NCT02487030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT02487030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT00983385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
Study NCT00983385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation period
Description: Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
Study NCT00983385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
Study NCT00189228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Patients are administered Xolair
Study NCT03960151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: Rolapitant 180mg PO, Days 1 and 5
Study NCT03960151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV, Days 1,3, and 5.
Study NCT02092025 — intervention group
Intervention type: DRUG
Intervention: Azilsartan
Description: Azilsartan tablets
Study NCT04689789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: optical coherence tomography angiography
Description: optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
Study NCT02161055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2
Study NCT02161055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2
Study NCT02361008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEE-guided perventricular device closure without CBP
Description: Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
Study NCT02361008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery repair with CBP
Description: Traditional surgery repair under the CBP.
Study NCT04598412 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study NCT03960151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
Study NCT03960151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg AM, Days 1,2 and 3
Study NCT03152539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03152539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT03152539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study NCT02457403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM
Description: Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
Study NCT02457403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
Study NCT02457403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
Study NCT02457403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
Study NCT02759666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: SHR3162 capsule(s) is administered orally QD.
Study NCT04384965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
Description: Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
Study NCT04330742 — intervention group
Intervention type: DRUG
Intervention: lactated ringers
Description: the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
Study NCT01707901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: Treatment
Study NCT01707901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01659684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: standard intravenous immunoglobulin
Description: Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
Study NCT02333786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis/in-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
Study NCT02333786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis/out-of-plane US-guided arterial catheterization
Description: Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
Study NCT01505816 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)
Description: Multifocal IOL implantation
Study NCT00900029 — intervention group
Intervention type: BIOLOGICAL
Intervention: No HP802 Treatment
Study NCT00900029 — intervention group
Intervention type: OTHER
Intervention: No HP802 Vehicle Treatment
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study NCT03117478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magneto-encephalography (MEG)
Description: Magneto-encephalography
Study NCT03117478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electro-encephalography (EEG)
Description: Electro-encephalography
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Administered twice during the study by injection
Study NCT03117478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging
Study NCT03117478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical Magnetic Resonance Imaging (aMRI)
Description: Anatomical Magnetic Resonance Imaging
Study NCT03117478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meditation
Description: Meditation
Study NCT01674777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT00741442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806
Description: Uricosuric agent for the treatment of gout
Study NCT00741442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo.
Study NCT01808235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Intervention
Description: The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
Study NCT03772665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily oral tablet taken for 24 months
Study NCT03772665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral tablet taken for 24 months
Study NCT02698150 — intervention group
Intervention type: DEVICE
Intervention: HERMES tablet
Description: Tablet, sensors and wearables for daily collection of clinical data
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Daily pill for 8 weeks
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Daily pill for 8 weeks